医学
基底细胞
肿瘤科
全身疗法
内科学
基底细胞癌
癌症
皮肤病科
癌
放射治疗
癌症研究
化疗
作者
Caitlin McMullen,Thomas J. Ow
标识
DOI:10.1016/j.otc.2020.11.007
摘要
Systemic therapy for patients with head and neck cutaneous squamous cell carcinoma (HNCSCC) generally is used for patients with advanced disease and most often employed for patients in the palliative setting when disease is unresectable and/or widely metastatic. Cytotoxic agents and epidermal growth factor receptor pathway targeted therapy have been utilized most commonly, with few clinical data to support their efficacy. Adjuvant postoperative chemoradiation with platinum has been called into question based on recent data. Programmed cell death protein 1 receptor immune checkpoint inhibitors have demonstrated profound activity in HNCSCC, and cemiplimab and pembrolizumab now are approved for use for unresectable/metastatic disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI